Magnolol reduces fatty liver injury in mice by blocking the MOGAT1 pathway

A natural compound found in the bark of Magnolia officinalis, a tree long used in traditional Chinese medicine, has been shown to protect mice from fatty liver disease, according to a new study that identifies the molecular pathway involved. In research published in Frontiers in Pharmacology, scientists at Nanchang University report that magnolol — also called 5,5′-diallyl-2,2′-dihydroxybiphenyl — lessened fat accumulation, inflammation and fibrotic changes in the livers of mice fed a high-fat diet. Using an unbiased gene-expression screen, the team found that Monoacylglycerol O-acyltransferase 1, or MOGAT1, was the most strongly suppressed lipid-metabolism gene after magnolol treatment, with a log2 fold change of −2.521 and an adjusted P value below 0.001.

The study used a tightly controlled experimental setup. Thirty male C57BL/6J mice, all eight weeks old and specific pathogen-free, were split at random into five groups of six. Two groups ate standard chow, including one that also received magnolol at 20 milligrams per kilogram, while the other three were given a high-fat diet in which 60 percent of calories came from fat for sixteen weeks. After that dietary period, the mice were treated daily for seven days with magnolol injections at 10 or 20 milligrams per kilogram, or with vehicle alone. The researchers chose injections instead of oral gavage because magnolol is highly lipophilic and undergoes extensive first-pass metabolism, which can make oral absorption inconsistent. The compound used in the study was more than 98 percent pure, as confirmed by high-performance liquid chromatography.

The benefits showed up across several measures of liver injury. Magnolol did not lower body weight, but it reduced the liver-to-body weight ratio in a dose-dependent manner, suggesting less fat deposition in the organ. Blood levels of alanine aminotransferase and aspartate aminotransferase, which rise when liver cells are damaged, were elevated in the high-fat diet group and dropped with treatment. Serum triglycerides, total cholesterol and low-density lipoprotein also declined. Microscopic examination using hematoxylin and eosin and Oil Red O staining showed the typical large lipid droplets of fatty liver in untreated mice, while these changes were much less pronounced after magnolol exposure. Expression of key lipogenesis genes, including Srebp1, Acaca and Fasn, was also reduced.

Fibrosis was the next major effect the researchers examined. Sirius red and Masson’s trichrome staining revealed substantial collagen buildup in the livers of high-fat-fed mice, and magnolol visibly lessened that scarring. The molecular markers told the same story: collagen type I, transforming growth factor-beta 1 and alpha-smooth muscle actin were all increased at both the messenger RNA and protein levels by the fatty diet, but moved back toward normal with magnolol. The authors interpret this as a reduction in active fibrogenesis rather than a reversal of established scar tissue, which fits the short treatment period and the relatively mild fibrosis seen in this model.

To determine how magnolol was acting at the molecular level, the team performed RNA sequencing on liver tissue from control mice, high-fat diet mice and high-fat diet mice treated with magnolol, using three biological replicates in each group. The high-fat diet altered hundreds of genes, with 476 increased and 380 decreased compared with chow-fed controls. Magnolol partly reversed that pattern, counteracting 69 of the genes induced by the diet. Pathway analysis pointed toward inflammatory signaling. MOGAT1 drew special attention because it encodes a rate-limiting enzyme that helps convert monoacylglycerol to diacylglycerol in triglyceride synthesis, and because hepatic MOGAT1 is known to rise in obesity and insulin resistance.

Correlation analyses added support to the findings. Across individual samples, MOGAT1 expression in the liver was positively associated with liver triglyceride content and serum alanine aminotransferase, linking the enzyme to both fat buildup and liver cell injury. Magnolol reduced the diet-induced increase in MOGAT1 at both the RNA and protein levels. The compound also acted on nuclear factor kappa B, or NF-κB, a major inflammatory signaling pathway. High-fat feeding increased phosphorylation of the P65 subunit and lowered IκBα protein, both hallmarks of NF-κB activation, and magnolol reversed those changes. Nuclear-cytoplasmic fractionation and immunofluorescence showed that P65 nuclear entry was blocked, while downstream inflammatory cytokines TNF-α, IL-6 and IL-1β were reduced at both the RNA and protein levels.

The strongest evidence came from cell culture experiments. The researchers exposed AML12 mouse hepatocytes to 200 micromolar sodium palmitate, a fatty acid used to mimic lipotoxic stress, with or without pretreatment using 5 or 10 micromoles per liter magnolol. Palmitate increased MOGAT1 expression, and magnolol lowered it in a dose-dependent way. They then carried out a rescue experiment by introducing a MOGAT1 overexpression plasmid. When MOGAT1 was forced back on, the protective effect of magnolol was largely lost. P65 phosphorylation and nuclear translocation returned, suppression of inflammatory cytokines and fibrotic markers such as COL1, TGF-β1 and ACTA2 was reversed, and even the reduction in reactive oxygen species measured by dihydroethidium staining was weakened. Taken together, the results suggest that MOGAT1 is a functional mediator of magnolol’s effects rather than a passive correlate.

The authors also note the limits of their work. Demonstrating that magnolol depends on MOGAT1 is not the same as proving direct binding, and no physical interaction between the compound and MOGAT1 — or its transcriptional regulators — has yet been shown. Methods such as surface plasmon resonance, cellular thermal shift assays or molecular docking would be needed to test that possibility. Other magnolol-responsive genes, including Scd1 and Cpt1a, may also contribute to the overall effect, which the researchers describe as likely polygenic rather than driven by a single target. They further caution that the MOGAT1 correlations were based on pooled group data and may reflect differences between groups, while the short treatment window mainly captures suppression of ongoing fibrogenic activity rather than true reversal of established fibrosis. The AML12 model also reflects changes inside hepatocytes, whereas fibrosis in the body involves stellate cells, Kupffer cells and extracellular matrix remodeling.

Questions about translation to humans remain open. Magnolol has a long history of traditional use and has been reported to have anti-inflammatory, antioxidant and anti-tumor properties, and the doses used in this work are within the range of earlier preclinical studies. Even so, the compound was delivered by injection, and it is unknown whether oral dosing could produce enough liver exposure to achieve similar effects. The authors call for pharmacokinetic and pharmacodynamic studies using clinically relevant oral formulations. They also acknowledge that, as a polyphenol, magnolol could in theory act as a pan-assay interference compound, although they argue that the dose-dependent cell data, the agreement with the animal results, the unbiased RNA-seq identification of MOGAT1 and the rescue experiment all argue against a nonspecific artifact. For now, the work offers a focused mechanistic model: a natural compound, a lipid-synthesis enzyme and a rescue experiment showing that restoring the enzyme removes the benefit.

Subject of Research: Magnolol's suppression of MOGAT1-mediated triglyceride synthesis and NF-κB signaling in high-fat diet-induced liver injury in mice

Article Title: Magnolol alleviates high-fat diet-induced steatosis, inflammation and fibrosis in obesity-associated liver injuries via MOGAT1-mediated lipid metabolism and NF-κB signaling

Article References: Huang, Z., Huang, Z., Luo, L., Wu, Z., Wen, Z., & Xiao, Z. (2026). Magnolol alleviates high-fat diet-induced steatosis, inflammation and fibrosis in obesity-associated liver injuries via MOGAT1-mediated lipid metabolism and NF-κB signaling. Frontiers in Pharmacology, 17, Article 1971993. https://doi.org/10.3389/fphar.2026.1971993

Image Credits: AI Generated

Keywords: magnolol, MOGAT1, fatty liver disease, NF-κB, hepatic steatosis, liver fibrosis, high-fat diet, NAFLD, Magnolia officinalis, triglyceride synthesis, mouse study, hepatocytes

Cite Scienmag News

Daisy Hatcher. Magnolol curbs fatty liver damage in mice by suppressing MOGAT1 enzyme. Scienmag. https://scienmag.com/magnolol-curbs-fatty-liver-damage-in-mice-by-suppressing-mogat1-enzyme/

Daisy Hatcher. "Magnolol curbs fatty liver damage in mice by suppressing MOGAT1 enzyme." Scienmag, https://scienmag.com/magnolol-curbs-fatty-liver-damage-in-mice-by-suppressing-mogat1-enzyme/. Accessed.